2017 RISE Poster HRS_20Mar2017_2

Report 1 Downloads 91 Views
Graduate Category: Physical and Life Sciences Degree Seeking: PhD in Chemistry Abstract ID# 1791

Role of Distal Residues in DNA Polymerases DinB and Pol Kappa in Bypass of DNA Damage Hannah R. Stern, Caitlyn L. Mills, Mary Jo Ondrechen, Penny J. Beuning Chemistry and Chemical Biology

Opportunity

Approach POOL predicts residues important for enzyme activity

DNA is subject to damage from endogenous and exogenous sources. Replicative DNA polymerases are typically unable to replicate damaged DNA, but specialized DNA polymerases in the Y family possess this ability. Escherichia coli has two Y family polymerases that are specialized to bypass lesions when copying damaged DNA in a process called translesion synthesis (TLS). DinB is one of these polymerases, which is involved in bypassing deoxyguanosine adducts at the N2 position, and is implicated in some antibiotic resistance. There are also four human Y family polymerases, including DNA Pol κ, that have similar function. However, Pol κ is more efficient in copying DNA damage in the extension step of TLS. In order to investigate the importance of particular residues in the extension step of TLS, the computational method POOL was utilized. POOL identified active site residues and residues previously observed to be important for activity. POOL also predicted distant residues that do not have direct contact with substrates that may have catalytic importance, but the residues are in different regions of DinB and Pol κ. In addition, our previous HXMS work suggested a possible allosteric change in both DinB and Pol κ in different distal residues that POOL did not predict. To study the contribution of these distal residues on the extension step of TLS, DinB and Pol κ variants with mutations at the predicted distal positions were constructed and are being assayed for bypass of damage lesions.

DinB and Pol κ are specific for minor groove damage

PDB: 1JDG

PDB: 1D65

PDB: 4IRC

Pol κ

DinB

Nevin, P., et al. (2015). FEBS Journal 282(14): 2646-2660.

Somarowthu, S., H. Yang, D.G.C. Hildebrand, and M.J. Ondrechen, Highperformance prediction of functional residues in proteins with machine learning and computed input features. Biopolymers, 2011. 95(6): 390-400.

PDB: 2OH2

Impact

Results Specific pattern of protection in polymerases due to substrate binding Protection from DNA Fingers

Palm

POOL Results with DinB and Pol κ show half of top 8% residues are conserved

Protection from DNA and dNTP Fingers

Fingers

Palm

E296

DinB Little Finger

Fingers

T248

Thumb Little Finger Palm N-clasp

Thumb

Little Finger

Thumb N-clasp

Little Finger

K289

N-clasp

Palm

Thumb

DinB

R211

Little Finger

Palm

Thumb

Y221

Palm

R330

Pol κ Little Finger

K224

Fingers

N-clasp

Thumb

Pol κ

Nevin, P., et al. (2015). FEBS Journal 282(14): 2646-2660.

• Residues in fingers domain are located near dNTP-binding site • Residues in little finger domain make contact with DNA • Residues in thumb were protected • Regions located distal to the active site • Sites do not make contacts with substrates • Substrate-dependent protection

• Value Proposition The unique feature about my research is: understanding the role of distal residues on enzyme activity and protein dynamics.

• Our goal is to determine which residues contribute to better extension by Pol κ compared with DinB • DinB non-conserved residues include three little finger residues • Non-conserved residues in Pol κ identified as part of the palm and N-clasp • By changing these residues, we can test enzyme activity to determine how these non-conserved residues play a role in the extension step of TLS

• Y-family DNA polymerases contribute to antibiotic resistance through their mutagenic DNA replication, prevent cancer by contributing to DNA damage tolerance, and contribute to chemotherapy resistance. Thus, this research addresses the problems of antibiotic resistance, some cancers, and chemotherapy resistance. Acknowledgments

Support from NSF-MCB-1517290, American Cancer Society RSG-12-161-01-DMC PhRMA Foundation (CLM)